CA2928631C - Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction - Google Patents

Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Info

Publication number
CA2928631C
CA2928631C CA2928631A CA2928631A CA2928631C CA 2928631 C CA2928631 C CA 2928631C CA 2928631 A CA2928631 A CA 2928631A CA 2928631 A CA2928631 A CA 2928631A CA 2928631 C CA2928631 C CA 2928631C
Authority
CA
Canada
Prior art keywords
acid
oral dosage
dosage form
solid oral
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2928631A
Other languages
English (en)
French (fr)
Other versions
CA2928631A1 (en
Inventor
Emilie Annie Claudie Fromentin
Douglas Andrew Klaiber
Daniel David Souza
Original Assignee
Naturex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2928631(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Naturex Inc filed Critical Naturex Inc
Priority to CA3277615A priority Critical patent/CA3277615A1/en
Publication of CA2928631A1 publication Critical patent/CA2928631A1/en
Application granted granted Critical
Publication of CA2928631C publication Critical patent/CA2928631C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2928631A 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction Active CA2928631C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3277615A CA3277615A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361902376P 2013-11-11 2013-11-11
US61/902,376 2013-11-11
PCT/US2014/064961 WO2015070203A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3277615A Division CA3277615A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Publications (2)

Publication Number Publication Date
CA2928631A1 CA2928631A1 (en) 2015-05-14
CA2928631C true CA2928631C (en) 2025-08-12

Family

ID=53042226

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2928631A Active CA2928631C (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
CA3277615A Pending CA3277615A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3277615A Pending CA3277615A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Country Status (21)

Country Link
US (5) US20160324911A1 (https=)
EP (2) EP3782634B1 (https=)
JP (2) JP6966196B2 (https=)
KR (2) KR102745710B1 (https=)
CN (2) CN105848663A (https=)
AU (1) AU2014346415B2 (https=)
BR (1) BR112016010509B1 (https=)
CA (2) CA2928631C (https=)
CL (1) CL2016001109A1 (https=)
CR (1) CR20160254A (https=)
ES (2) ES2980381T3 (https=)
IL (1) IL245552B (https=)
MX (1) MX373448B (https=)
MY (1) MY184225A (https=)
NZ (1) NZ719268A (https=)
PH (1) PH12016500780A1 (https=)
PL (1) PL3068414T3 (https=)
RU (1) RU2696584C1 (https=)
SG (2) SG10201910781SA (https=)
WO (1) WO2015070203A1 (https=)
ZA (1) ZA201602941B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102745710B1 (ko) * 2013-11-11 2024-12-20 나투렉스 인코포레이티드 하부 요로 증상, 양성 전립선 비대증, 발기부전 치료에 유용한 조성물 및 방법
WO2018134962A1 (ja) * 2017-01-20 2018-07-26 マルカイコーポレーション株式会社 頻尿の改善剤
CN107647387A (zh) * 2017-08-15 2018-02-02 孟广千 用于补膀胱的保健食品
IT201800007473A1 (it) 2018-07-24 2020-01-24 Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo
JP7219907B2 (ja) * 2018-07-25 2023-02-09 株式会社 沖縄リサーチセンター 下部尿路症状改善用組成物
JP6738388B2 (ja) * 2018-09-27 2020-08-12 マルカイコーポレーション株式会社 頻尿の改善剤
US20200360466A1 (en) * 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US20220400727A1 (en) * 2019-11-08 2022-12-22 Cj Cheiljedang Corporation Composition containing polyphenol
EP4205756A4 (en) * 2020-08-31 2024-10-23 K-Biotech Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF ABELIOPHYLLUM DISTICHUM AS ACTIVE INGREDIENT FOR TREATING AN ANDROGEN RECEPTOR-RELATED DISEASE
WO2022189010A1 (en) * 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
KR102388984B1 (ko) * 2021-11-16 2022-04-20 재단법인 전남바이오산업진흥원 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물
WO2025038998A1 (en) * 2023-08-17 2025-02-20 University Of Wyoming Materials and methods for inhibiting, preventing, and dispersing biofilms
WO2025078239A1 (en) 2023-10-09 2025-04-17 Givaudan Sa Compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6231866B1 (en) * 1998-04-30 2001-05-15 Douglas G. Mann Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same
US20010025059A1 (en) 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
JP2001342142A (ja) * 2000-06-01 2001-12-11 Nissui Pharm Co Ltd 泌尿器系疾患予防治療用組成物
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
EP1727522A2 (en) * 2004-02-04 2006-12-06 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
CA2580628C (en) * 2004-05-03 2014-08-19 Northern Lights Food Processing, Llc Berry oils and products
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
CN101784279A (zh) * 2007-06-27 2010-07-21 科洛普拉斯特公司 使用皂角苷和抗生素的混合物治疗泌尿道感染
CN101095764B (zh) * 2007-07-13 2010-05-19 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US8173178B1 (en) 2007-08-03 2012-05-08 Decas Botanical Synergies, Llc Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs)
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
US20110064706A1 (en) 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
EP2156835A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
WO2011088420A1 (en) 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
CN101999648B (zh) * 2010-10-11 2012-10-31 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法
JP2012171899A (ja) * 2011-02-21 2012-09-10 Unitika Ltd 尿路感染症予防改善剤
FR2972328A1 (fr) * 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
US20130122146A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food
KR102745710B1 (ko) * 2013-11-11 2024-12-20 나투렉스 인코포레이티드 하부 요로 증상, 양성 전립선 비대증, 발기부전 치료에 유용한 조성물 및 방법

Also Published As

Publication number Publication date
JP6966196B2 (ja) 2021-11-10
RU2016122062A (ru) 2017-12-19
ES2860773T3 (es) 2021-10-05
KR102476969B1 (ko) 2022-12-12
JP2016539183A (ja) 2016-12-15
US20180256663A1 (en) 2018-09-13
EP3068414A4 (en) 2017-06-07
IL245552A0 (en) 2016-06-30
EP3068414A1 (en) 2016-09-21
IL245552B (en) 2020-07-30
BR112016010509B1 (pt) 2021-08-17
NZ719268A (en) 2021-07-30
KR20230004886A (ko) 2023-01-06
CL2016001109A1 (es) 2016-12-02
PH12016500780B1 (en) 2016-06-13
AU2014346415B2 (en) 2020-04-23
EP3782634A1 (en) 2021-02-24
US20200121750A1 (en) 2020-04-23
EP3068414B1 (en) 2020-12-30
US10898534B2 (en) 2021-01-26
RU2696584C1 (ru) 2019-08-05
BR112016010509A2 (pt) 2017-08-08
MX2016005810A (es) 2016-11-18
MX373448B (es) 2020-06-11
US11045511B2 (en) 2021-06-29
ZA201602941B (en) 2022-05-25
US20220175863A1 (en) 2022-06-09
AU2014346415A1 (en) 2016-05-12
ES2980381T3 (es) 2024-10-01
US20160324911A1 (en) 2016-11-10
US12233101B2 (en) 2025-02-25
JP7083330B2 (ja) 2022-06-10
MY184225A (en) 2021-03-28
PL3068414T3 (pl) 2021-08-30
SG10201910781SA (en) 2020-01-30
CR20160254A (es) 2016-08-31
CN105848663A (zh) 2016-08-10
JP2020059725A (ja) 2020-04-16
CA2928631A1 (en) 2015-05-14
SG11201603462SA (en) 2016-05-30
WO2015070203A1 (en) 2015-05-14
KR20160079884A (ko) 2016-07-06
WO2015070203A9 (en) 2016-01-14
US20190358282A1 (en) 2019-11-28
CN116077548A (zh) 2023-05-09
CA3277615A1 (en) 2025-10-30
EP3782634B1 (en) 2024-03-20
KR102745710B1 (ko) 2024-12-20
PH12016500780A1 (en) 2016-06-13
US11291703B2 (en) 2022-04-05

Similar Documents

Publication Publication Date Title
US12233101B2 (en) Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and other diseases or symptoms
Singh et al. Health benefits of resveratrol: Evidence from clinical studies
Cao et al. Alleviation of glucolipotoxicity-incurred cardiomyocyte dysfunction by Z-ligustilide involves in the suppression of oxidative insult, inflammation and fibrosis
Kumaran et al. Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: A double blind, placebo-controlled study
US20240325346A1 (en) Methods and compositions for treating congenital diarrhea disorder
JP2013528163A (ja) 心臓血管疾患を治療するためのリンゴ果皮抽出物
JP2019504117A (ja) 前立腺過形成の処置のための医薬組成物
HK1228782B (en) Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
HK1228782A1 (en) Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
Vanachayangkul Ammi visnaga L. for the prevention of urolithiasis
Aloud Effects of cyanidin 3-O-glucoside on cardiovascular complications and immune response in spontaneously hypertensive rats
US20130149277A1 (en) Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191023

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250213

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250619

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250708

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250708

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250808

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260120